Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29579939 | 1.00 | DHFR (1.00) | DHFRSLC2A1 | |
| SCHEMBL14870312 | 0.86 | DHFR (0.77) | DHFRSLC2A1 | |
| SCHEMBL29546342 | 0.81 | DHFR (0.71) | DHFRSLC2A1 | |
| SCHEMBL14872561 | 0.81 | DHFR (0.71) | DHFRSLC2A1 | |
| Bromide SCHEMBL9395278 | 0.80 | DHFR (0.66) | DHFRSLC2A1 | |
| Bromide SCHEMBL9396234 | 0.80 | DHFR (0.66) | DHFRSLC2A1 | |
| SCHEMBL8934111 | 0.78 | DHFR (0.67) | DHFR | |
| SCHEMBL8934103 | 0.78 | SLC2A1 (0.71) | DHFRSLC2A1 | |
| Bromide SCHEMBL9395252 | 0.77 | DHFR (0.62) | DHFR | |
| Hydrochloric Acid SCHEMBL9395519 | 0.76 | DHFR (0.61) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996015671-A1 | HERBICIDES | ZENECA LIMITED (GB) | 1996-05-30 | — | — | WO | claimed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| EP-2464353-B1 | TRIAZINE DERIVATIVES FOR USE IN THE TREATMENT OF MALARIA | CSIR (ZA) | 2017-03-29 | — | — | EP | disclosed |
| US-8940892-B2 | Triazine derivatives for use in the treatment of malaria | CSIR (ZA) | 2015-01-27 | — | — | US | disclosed |
| US-20120142920-A1 | TRIAZINE DERIVATIVES FOR USE IN THE TREATMENT OF MALARIA | CSIR (ZA) | 2012-06-07 | — | — | US | disclosed |
| WO-2011018742-A1 | TRIAZINE DERIVATES FOR USE IN THE TREATMENT OF MALARIA | CSIR (ZA) | 2011-02-17 | — | — | WO | disclosed |
| EP-0831806-A1 | MULTIDENTATE METAL COMPLEXES AND METHODS OF MAKING AND USING THEREOF | WASHINGTON UNIVERSITY (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040108-A1 | MULTIDENTATE METAL COMPLEXES AND METHODS OF MAKING AND USING THEREOF | WASHINGTON UNIVERSITY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996015671-A1 | HERBICIDES | ZENECA LIMITED (GB) | 1996-05-30 | — | — | WO | disclosed |
| WO-1996015672-A1 | FUNGICIDAL COMPOSITION | ZENECA LIMITED (GB) | 1996-05-30 | — | — | WO | disclosed |
| US-5270037-A | Use of interferon and a substance with an antimalarial activity for the treatment of malaria infections | BOEHRINGER INGELHEIM GMBH (DE) | 1993-12-14 | — | — | US | disclosed |
| EP-0490250-A2 | Use of interferon and an antimalarial agent for the treatment of malarial infections | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 1992-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142920-A1 | TRIAZINE DERIVATIVES FOR USE IN THE TREATMENT OF MALARIA | CYP3A7, CCR7, CYP3A5 | DHFR 32/4885SLC2A1 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.